Clinical Trial Update: A Study of LY2835219 in Participants With Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of LY2835219 in participants with cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasm
• Neoplasm Metastasis

Drugs mentioned

• LY2835219 (LY2835219)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Neoplasm, Neoplasm Metastasis | Phase 1 | Status: COMPLETED | Results posted: 2018-08-02